In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
In the latest session, Avidity Biosciences Inc (NASDAQ: RNA) closed at $31.37 down -2.40% from its previous closing price of $32.14. In other words, the price has decreased by -$2.40 from its previous closing price. On the day, 0.96 million shares were traded.
Ratios:
For a deeper understanding of Avidity Biosciences Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 16.91 and its Current Ratio is at 16.91. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Raymond James on June 11, 2025, initiated with a Strong Buy rating and assigned the stock a target price of $65.
On March 13, 2025, Citigroup started tracking the stock assigning a Buy rating and target price of $70.
On March 12, 2025, BMO Capital Markets started tracking the stock assigning a Outperform rating and target price of $72.BMO Capital Markets initiated its Outperform rating on March 12, 2025, with a $72 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jun 11 ’25 when Flanagan W. Michael sold 20,000 shares for $32.88 per share. The transaction valued at 657,694 led to the insider holds 80,195 shares of the business.
WILLIAM MICHAEL FLANAGAN bought 20,000 shares of RNA for $672,400 on Jun 11 ’25. On Jun 02 ’25, another insider, Gallagher Kathleen P., who serves as the Chief Program Officer of the company, sold 5,875 shares for $32.48 each. As a result, the insider received 190,833 and left with 50,554 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 423.44 while its Price-to-Book (P/B) ratio in mrq is 2.85.
Stock Price History:
Over the past 52 weeks, RNA has reached a high of $56.00, while it has fallen to a 52-week low of $21.51. The 50-Day Moving Average of the stock is 4.74%, while the 200-Day Moving Average is calculated to be -11.92%.
Shares Statistics:
A total of 120.51M shares are outstanding, with a floating share count of 109.84M. Insiders hold about 8.88% of the company’s shares, while institutions hold 107.71% stake in the company.
Earnings Estimates
The current rating of Avidity Biosciences Inc (RNA) reflects the combined expertise of 14.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$1.02, with high estimates of -$0.61 and low estimates of -$1.47.
Analysts are recommending an EPS of between -$2.71 and -$5.36 for the fiscal current year, implying an average EPS of -$3.97. EPS for the following year is -$4.46, with 15.0 analysts recommending between -$2.65 and -$5.64.
Revenue Estimates
A total of 11 analysts have provided revenue estimates for RNA’s current fiscal year. The highest revenue estimate was $13.18M, while the lowest revenue estimate was $1.6M, resulting in an average revenue estimate of $7.72M. In the same quarter a year ago, actual revenue was $10.9M
